Comparative study on Jinghua Weikang Capsule and famotidine in treating duodenal ulcer.
- Author:
Feng JI
1
;
Jian-yong CHEN
;
Jun-xian CHEN
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Anti-Ulcer Agents; therapeutic use; Drug Therapy, Combination; Drugs, Chinese Herbal; therapeutic use; Duodenal Ulcer; drug therapy; microbiology; Famotidine; therapeutic use; Female; Helicobacter Infections; drug therapy; microbiology; Helicobacter pylori; drug effects; Humans; Male; Middle Aged; Phytotherapy; Treatment Outcome
- From: Chinese Journal of Integrated Traditional and Western Medicine 2006;26(4):357-360
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare the effect and security of Jinghua Weikang Capsule (JWC) and famotidine in treating duodenal ulcer.
METHODSTwo hundred patients with duodenal ulcer were randomly divided into the treated group treated with JWC, 160 mg 3 times per day and the control group treated with famotidine 20 mg twice per day, both by orally taking before meal for 4 weeks, 100 cases in each group. Changes of symptom score, adverse reaction, helicobacter pylori (Hp) infection and endoscopic figure before and after treatment were observed.
RESULTSThe general remission rate and the ulcer healing rate in the treated group were equal to those in the control group respectively (both P > 0.05). Symptoms including belly ache, sour regurgitation and abdominal distension were ameliorated after therapy in both groups (all P < 0.05). The effect in relieving anorexia and eructation and Hp eradication rate were significantly higher in the treated group than those in the control group (all P< 0.05), while the incidence rate of adverse reaction in the treated group was remarkably lower than that in the control group (P < 0.05).
CONCLUSIONJWC is an effective and safe remedy in treating duodenal ulcer, especially for symptom amelioration and Hp eradication, so it is worthy of expanding clinically.
